SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.

For people having surgery unrelated to their hearts, new guidelines detail how to manage heart and stroke risks before, ...

Noninvasive, low‐level tragus stimulation modestly reduced blood pressure (BP) in relatively healthy people with grade 1 ...

SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

A team at the Hübner and Diecke Labs at the Max Delbrück Center has shown how human and non-human primate hearts differ ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

The American Heart Association and the American College of Cardiology joint guideline addressing cardiovascular evaluation ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.